Shares
of BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) fell $0.99 (40%) to $1.46 on
Thursday after the company discontinued for futility the Phase III BCX1812-301
trial of peramivir to treat patients hospitalized for serious influenza
infection.
And do you
know what? Peramivir is very-very targeted drug: Peramivir is a
neuraminidase inhibitor, acting as a transition-state analogue inhibitor of
influenza neuraminidase and thereby preventing new viruses from emerging from
infected cells.
Well, something
is very wrong with the targeted approach!
Who will
fail next?
No comments:
Post a Comment